Peptide profile

Melanotan I

AHuman-validated 🟡Yellow See the side-effect detail ↓

What do these badges mean?

Evidence tier

AHuman-validated — Human trials showing positive results and good safety.
BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
CAnecdotal — No human or animal trials — only anecdotal/observational reports.
DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).

Safety light

🟢 Green — Only mild, manageable side effects; reasonable safety data.
🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
🔴 Red — Risk of a hospital-level event — treat with serious caution.

Build a protocol →

Tanning / pigment

Question 1

What is it?

There are two molecules called “Melanotan,” and confusing them is the single most common mistake in this corner of peptides. Here’s the clean split:

Melanotan I (afamelanotide, brand SCENESSE) — this page. A 13-amino-acid linear analog of α-MSH (the body’s own melanocyte-stimulating hormone), relatively selective for the MC1R “tanning” receptor. It’s an FDA-approved drug, delivered as a clinician-placed implant for a rare light-sensitivity condition.
Melanotan II (MT-II) — a cyclic, non-selective melanocortin agonist that hits MC1R plus MC3R/MC4R/MC5R, which is why it also drives libido, appetite suppression, nausea, and erections. That’s the molecule Alyve sells and the subject of the Melanotan II page.

The practical headline: same tanning pathway, much narrower footprint. Melanotan I’s selectivity is exactly why it made it through clinical trials to FDA approval while MT-II never did. The full chemical name you’ll see is [Nle4-D-Phe7]-α-MSH (NDP-MSH) — two amino-acid swaps that make α-MSH potent and metabolically stable.

Question 2

What does it do in my body?

Melanotan I is a selective MC1R agonist. When it binds MC1R on your melanocytes, those cells ramp up production of eumelanin — the brown/black pigment that’s the protective form of melanin — and they do it independent of UV exposure. Normally you need sunlight to trigger this; Melanotan I triggers it pharmacologically, so pigment develops with little or no sun.

Eumelanin isn’t just color. It absorbs and scatters UV and visible light and mops up the reactive oxygen species that light generates in skin. That’s why the approved use is photoprotection: in erythropoietic protoporphyria (EPP), sunlight triggers a painful phototoxic reaction, and more eumelanin raises the light threshold before the pain starts.

The difference from MT-II comes down to receptor selectivity. MT-II is a shotgun across the melanocortin receptor family (MC1R–MC5R); the MC3R/MC4R hits are what produce its libido, appetite, nausea, yawning, and priapism effects. Melanotan I is comparatively focused on MC1R, so it largely skips that off-target package — you get the pigment without most of the rest.

Question 3

How can it help me?

Best fit: Melanocortin-driven tanning/photoprotection with a cleaner side-effect profile than MT-II; the molecule behind the FDA-approved EPP photoprotection drug
Where the science stands: FDA-approved (2019, SCENESSE) on Phase 3 RCT data + human PK/pigmentation studies

The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.

Question 4 & 5

Is it dangerous? What are the side effects?

Melanotan I’s selectivity is the story here: it’s meaningfully better tolerated than MT-II because it largely skips the MC3R/MC4R receptors that drive MT-II’s nausea, appetite, erection, and priapism effects.

Common / mild (approved-implant profile): implant-site reactions, headache, fatigue, and nausea at a much lower rate than MT-II. Mild skin darkening and new freckling are expected — that’s the drug working.
Skin/mole changes — the one to watch. Melanotan I stimulates all melanocytes, including those in existing moles. So although there’s no melanoma-screening urgency at the MT-II level, a baseline skin/mole check and periodic monitoring is the sensible practice — and it’s exactly what EPP patients do under clinical supervision. Anyone using gray-market MT-I powder without a clinician should adopt the same habit themselves.
No priapism signal and minimal libido/appetite effect — the MC1R selectivity is why. This is the clean contrast to MT-II’s profile.

The honest framing: this is the milder, cleaner melanocortin tanner. The main residual caution is the shared melanocyte-stimulation biology (mole monitoring), plus the usual gray-market caveat below.

The supply-chain caveat. “MT-I” sold as research powder carries the standard identity/purity risk — and MT-I and MT-II are routinely confused and mislabeled. A buyer of unverified powder genuinely can’t be sure which molecule (or what purity) is in the vial. With melanocortins, identity verification is the whole game.

Regulatory status:

Melanotan I / afamelanotide (SCENESSE): FDA-approved October 8, 2019 to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP); delivered as a clinician-placed 16 mg implant every 2 months. EU-approved 2014 for the same indication. Not approved for cosmetic tanning anywhere.
Research-grade MT-I powder: unapproved, sold research-use-only, and (per directory sources) not eligible for compounding. Those are the regulatory facts, stated plainly — the approved implant and the gray-market powder are the same molecule but very different products and legal statuses.

Preparing it

Part 1 — How to reconstitute it

What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.

The exact bacteriostatic-water volume and resulting concentration for Melanotan I are covered in the dosing notes and the deeper-science view. Confirm the right volume for your vial before mixing.

How to mix it

Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
Swirl gently to dissolve. Never shake — shaking can damage the peptide.
Store the reconstituted vial refrigerated and out of light.
Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.

Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.

Dosing

Part 2 — Typical dosing

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.

The approved form (SCENESSE / afamelanotide): a single bioresorbable 16 mg implant, placed subcutaneously by a clinician above the anterior supra-iliac crest (hip), every 2 months, for EPP photoprotection. This is a clinician-administered drug, not a self-injected one.

The gray-market / research-powder form (off-label tanning): MT-I is sold as lyophilized powder and reconstituted with bacteriostatic water like other peptides, then injected subcutaneously. Because oral MT-I isn’t absorbed, SC is the route. There’s no standardized cosmetic protocol the way there is for MT-II; community use mirrors the MT-II low-and-slow pattern (small SC microdoses to build pigment, then taper to maintenance), with some light exposure to develop the tan.

Practical notes from the PK data. Pigment builds over days and peaks about a week after dosing, then persists for weeks — so this is a build-and-maintain compound, not an on-demand one. Reconstituted peptide is stored refrigerated.

Turning milligrams into syringe units. On a U-100 syringe, 100 units = 1 mL, so 1 unit = 0.01 mL. At a concentration of C mg/mL, a dose of D mg = D ÷ C mL = (D ÷ C) × 100 units. Example: at 5 mg/mL, a 0.5 mg dose = 0.1 mL = 10 units. Your exact units depend on your own vial's mg and how much bacteriostatic water you added — use the same concentration you mixed above.

Question 7 & 8

What should I avoid combining — and what's synergistic?

Melanotan I doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.

Question 9

How can I buy this?

We don't have a verified affiliate source for Melanotan I yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.

Full scientific article — every section, citations intact. Use the toggle above to return to the practical view.

Melanotan I is the other melanotan — and it’s the one that actually carries an FDA approval. It’s a selective MC1R agonist that tells your skin to make protective brown pigment with little or no sun, and as the implant SCENESSE (afamelanotide) it’s an approved drug (2019) for a rare light-sensitivity disease. Because it’s selective for the “tanning” receptor and skips the receptors that drive Melanotan II’s libido, appetite, nausea and priapism effects, it’s a cleaner, better-tolerated molecule than its non-selective cousin Melanotan II (MT-II). This page covers Melanotan I specifically — what it is, how it works, the real trial data, the protocol, the side effects, and the regulatory facts.

Best fit	Melanocortin-driven tanning/photoprotection with a cleaner side-effect profile than MT-II; the molecule behind the FDA-approved EPP photoprotection drug
Evidence base	FDA-approved (2019, SCENESSE) on Phase 3 RCT data + human PK/pigmentation studies
Typical use	Approved: clinician-placed 16 mg implant every 2 months (EPP). Gray-market powder: reconstituted SC injection for tanning (off-label, unapproved)
Safety	Yellow — well-tolerated and MC1R-selective (far milder than MT-II), but still a melanocyte stimulant, so mole monitoring is prudent
Regulatory	FDA-approved 2019 as SCENESSE (afamelanotide) for erythropoietic protoporphyria; the research-powder form is unapproved/research-use-only

What it is

There are two molecules called “Melanotan,” and confusing them is the single most common mistake in this corner of peptides. Here’s the clean split:

Melanotan I (afamelanotide, brand SCENESSE) — this page. A 13-amino-acid linear analog of α-MSH (the body’s own melanocyte-stimulating hormone), relatively selective for the MC1R “tanning” receptor. It’s an FDA-approved drug, delivered as a clinician-placed implant for a rare light-sensitivity condition.
Melanotan II (MT-II) — a cyclic, non-selective melanocortin agonist that hits MC1R plus MC3R/MC4R/MC5R, which is why it also drives libido, appetite suppression, nausea, and erections. That’s the molecule Alyve sells and the subject of the Melanotan II page.

How it works

What the research shows

Unlike MT-II — whose human dataset is two small, decades-old studies — Melanotan I has approval-grade evidence behind it, because the pharma program (Clinuvel) actually ran it to the finish line.

** Phase 3 — the approval data (Langendonk 2015).** Two randomized, placebo-controlled trials (a European and a US trial) tested the afamelanotide implant every 60 days against placebo in EPP patients. Afamelanotide significantly increased the duration of pain-free sun exposure and improved quality of life, with an acceptable adverse-event profile. The FDA pivotal readout: over 180 days, median 64 pain-free sunlight hours on drug vs 41 on placebo — the basis for the 2019 approval.

** Pharmacokinetics + pigmentation (Ugwu 1997).** In a 3-subject IV/oral/SC crossover, the subcutaneous dose was completely bioavailable (equivalent to IV), while the oral dose wasn’t absorbed at all (no detectable drug). Plasma β-phase half-life was short (~0.8–1.7 h). Visible tanning of the forehead, arms and neck peaked about a week after dosing and was still present ~3 weeks after the regimen ended. This is the study that established MT-I tans the skin and that the SC route works.

** Eumelanin induction (Dorr 2000).** A human study reported a 49–98% increase in skin eumelanin content after a two-week MT-I course — direct confirmation that the pigment being made is the protective eumelanin, not just surface color.

** Broader photoprotection context.** Reviews place afamelanotide’s photoprotective potential across photosensitivity disorders and as a research candidate for nonmelanoma skin-cancer prevention.

Long-term safety record. Afamelanotide has a multi-year post-approval and observational safety record in EPP under clinical supervision — durable quality-of-life and light-tolerance benefit, no serious drug-related adverse events in the long-term cohorts, including a 2026 Austrian EPP cohort.

Where it stands: Melanotan I is the well-trialed melanocortin tanning agent. Its evidence base is an FDA approval built on Phase 3 RCTs — a different universe from MT-II’s thin, old human dataset. The catch is that the approved evidence is all in the photoprotection (EPP) setting via the implant; cosmetic tanning with research-grade MT-I powder rides on the same biology but is off-label and unapproved.

Real-world protocol

The doses and schedules here are for educational and informational purposes only. The approved implant is a prescription drug; the research-grade powder is sold for research use only and is not an FDA-approved drug. This is not medical advice. Consult a qualified physician before beginning any protocol.

Side effects & management

Common / mild (approved-implant profile): implant-site reactions, headache, fatigue, and nausea at a much lower rate than MT-II. Mild skin darkening and new freckling are expected — that’s the drug working.
Skin/mole changes — the one to watch. Melanotan I stimulates all melanocytes, including those in existing moles. So although there’s no melanoma-screening urgency at the MT-II level, a baseline skin/mole check and periodic monitoring is the sensible practice — and it’s exactly what EPP patients do under clinical supervision. Anyone using gray-market MT-I powder without a clinician should adopt the same habit themselves.
No priapism signal and minimal libido/appetite effect — the MC1R selectivity is why. This is the clean contrast to MT-II’s profile.